Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Pasquale Rescigno.

Newcastle AuthorsTitleYearFull text
Dr Pasquale Rescigno
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study2024
Dr Pasquale Rescigno
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)2024
Dr Pasquale Rescigno
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”2024
Dr Pasquale Rescigno
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies2024
Dr Pasquale Rescigno
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial2024
Dr Pasquale Rescigno
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer2024
Professor Alastair Greystoke
Professor Ruth Plummer
Dr Christoph Oing
Dr Pasquale Rescigno
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis2024
Dr Pasquale Rescigno
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations2024
Dr Christoph Oing
Dr Pasquale Rescigno
Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review2024
Dr Pasquale Rescigno
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care2024
Dr Pasquale Rescigno
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study2024
Dr Pasquale Rescigno
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study)2024
Dr Pasquale Rescigno
Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma2024
Dr Pasquale Rescigno
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study2024
Dr Pasquale Rescigno
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study2024
Dr Pasquale Rescigno
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)2024
Dr Pasquale Rescigno
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab2024
Dr Pasquale Rescigno
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study2024
Dr Christoph Oing
Dr Pasquale Rescigno
Retroperitoneal Lymph Node Dissection in Patients with Stage II Seminomatous Germ Cell Tumour2024
Dr Pasquale Rescigno
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study2024
Dr Pasquale Rescigno
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy2024
Dr Pasquale Rescigno
The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients2024
Dr Pasquale Rescigno
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study2024
Dr Pasquale Rescigno
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score2023
Dr Pasquale Rescigno
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer2023
Dr Pasquale Rescigno
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer2023
Dr Pasquale Rescigno
Basal cell carcinoma of the prostate: a case report of a rare prostate cancer and review of the literature2023
Dr Pasquale Rescigno
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study2023
Dr Pasquale Rescigno
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report2023
Dr Pasquale Rescigno
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224–38] (European Urology (2023) 83(3) (224–238), (S0302283822026331), (10.1016/j.eururo.2022.09.004))2023
Dr Christoph Oing
Dr Pasquale Rescigno
Genomic tests for persistence PSA after radical prostatectomy: smoke and mirrors or new effective tools for the clinical decision-making?2023
Dr Pasquale Rescigno
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score2023
Dr Pasquale Rescigno
Prognostic models for patients with metastatic urothelial carcinoma: why use them?2023
Dr Pasquale Rescigno
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP)2023
Dr Pasquale Rescigno
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab2023
Dr Beth Adamson
Nicholas Brittain
Dr Laura Walker
Ruaridh Duncan
Dr Sara Luzzi
et al.		The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer2023
Dr Pasquale Rescigno
The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review2023
Dr Pasquale Rescigno
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network2023
Dr Pasquale Rescigno
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis2023
Dr Pasquale Rescigno
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network2022
Dr Pasquale Rescigno
Gene expression profiles and treatments for metastatic renal cell carcinoma: What does still need to be defined?2022
Dr Pasquale Rescigno
Imaging features of the evolving patterns of metastatic prostate cancer2022
Dr Dan Westaby
Dr Pasquale Rescigno
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer2022
Dr Pasquale Rescigno
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives2022
Dr Pasquale Rescigno
Re: Commensal Bacteria Promote Endocrine Resistance in Prostate Cancer through Androgen Biosynthesis2022
Dr Pasquale Rescigno
Standard versus high-dose chemotherapy in mediastinal germ cell tumors: A narrative review2022
Dr Pasquale Rescigno
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network2022
Dr Pasquale Rescigno
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study2022
Dr Pasquale Rescigno
The real-time intraoperative guidance of the new HIFU Focal-One® platform allows to minimize the perioperative adverse events in salvage setting2022
Dr Pasquale Rescigno
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study2022
Dr Pasquale Rescigno
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program2022
Dr Pasquale Rescigno
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors2021
Dr Pasquale Rescigno
Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial2021
Dr Pasquale Rescigno
Characterizing CDK12-mutated prostate cancers A C2021
Dr Pasquale Rescigno
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis2021
Dr Pasquale Rescigno
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA2021
Dr Pasquale Rescigno
Erratum to 'Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis' [Eur J Cancer 149 (2021) 134–152] (European Journal of Cancer (2021) 149 (134–152), (S095980492100143X), (10.1016/j.ejca.2021.02.035))2021
Dr Pasquale Rescigno
HER3 Is an Actionable Target in Advanced Prostate Cancer2021
Dr Pasquale Rescigno
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients2021
Dr Pasquale Rescigno
In Reply2021
Dr Pasquale Rescigno
Molecular characterization of prostate cancers in the precision medicine era2021
Dr Pasquale Rescigno
New prognostic biomarkers in metastatic castration-resistant prostate cancer2021
Dr Pasquale Rescigno
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis2021
Dr Pasquale Rescigno
Prognostic and predictive factors in advanced urothelial carcinoma treated with immune checkpoint inhibitors: A review of the current evidence2021
Dr Pasquale Rescigno
The emerging role of whole-body magnetic resonance imaging in advanced prostate cancer2021
Dr Pasquale Rescigno
The enigmatic role of TP53 in germ cell tumours: Are we missing something?2021
Dr Pasquale Rescigno
Value of early circulating tumor cells dynamics to estimate docetaxel benefit in metastatic castration-resistant prostate cancer (mCRPC) patients2021